Publications

1. Advice on the clustering of combination products and ghost clusters in GVS (part 1)

   The Minister of Medical Care has asked Zorginstituut Nederland questions about the clustering of two categories of medicinal ...

   Report | 04-05-2021

2. GVS advice elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in combination with ivacaftor (Kalydeco®)

   The National Health Care Institute has completed its assessment whether elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in ...

   Report | 29-04-2021

3. GVS assessment of trientine dihydrochloride (Cufence®) for the treatment of Wilson’s disease

   The National Health Care Institute has completed its assessment whether trientine dihydrochloride (Cufence®) can be included in ...

   Report | 19-04-2021

4. GVS assessment of crisaborole (Staquis®) for the treatment of atopic dermatitis

   The National Health Care Institute has completed its assessment whether crisaborole (Staquis®) is interchangeable with a product ...

   Report | 15-04-2021

5. GVS assessment of rivaroxaban (Xarelto®) for the treatment of VTE and prevention of VTE recurrence in children

   The National Health Care Institute has completed its assessment whether rivaroxaban (Xarelto®) 1 mg/ml suspension can be included ...

   Report | 17-03-2021

6. Advice on a potential candidate for conditional inclusion of entrectinib (Rozlytrek®) for solid tumours with NTRK gene fusion

   Zorginstituut Nederland recommends that entrectinib should be designated as a potential candidate for conditional inclusion. ...

   Letter | 10-03-2021

7. Advice on a potential candidate for conditional inclusion of larotrectinib (Vitrakvi®) for solid tumours with NTRK gene fusion

   Zorginstituut Nederland recommends that larotrectinib should be designated as a potential candidate for conditional inclusion. ...

   Letter | 10-03-2021

8. GVS assessment of 13-valent pneumococcal conjugate vaccine (Prevenar13®) for medical high-risk groups

   The National Health Care Institute has completed its assessment whether 13-valent pneumococcal conjugate vaccine (PVC13; ...

   Report | 03-03-2021

9. GVS assessment of Brimonidine Stulln 2mg/ml eye drop solution for decrease of increased intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

   The National Health Care Institute has completed its assessment whether Brimonidine Stulln 2mg/ml eye drop solution, single-use ...

   Report | 24-02-2021

10. GVS assessment of formoterol/ glycopyrronium/ budesonide (Trixeo® aerosphere)

    The National Health Care Institute has completed its assessment whether the product formoterol/glycopyrronium/budesonide (Trixeo® ...

    Report | 22-02-2021